Recent Updates in The Role of Immunotherapies in Early NSCLC: Translating Evidence to Clinical Practice - Episode 12
Treatment for Patients Unsuitable for or Refractory to Consolidation Durvalumab
Tina Cascone, MD, Ben Levy, MD, and Sandip Patel, MD, offer insights into the treatment approach in patients with unresectable early-stage NSCLC who are unsuitable for consolidation durvalumab or who progress on consolidation durvalumab.
Related Content:
